Advertisement
![Picture [iito] Männer Ballett 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-maenner-ballett.jpg)
Organisation › Details
MorphoSys (Group)
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *
![]() |
Start | 1992-01-01 established |
Today | MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR) | |
Predecessor | Max Planck Society for the Advancement of Science | |
![]() |
Industry | biopharmaceutical |
![]() |
Person | Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme) |
Person 2 | Holstein, Jens (MorphoSys 201105–202012 CFO before Fresenius Kabi RESIGNED 12/20) | |
![]() |
Region | Martinsried |
Country | Germany | |
Street | 7 Semmelweisstr. | |
City | 82152 Planegg | |
Tel | +49-89-89927-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2019-12-31) |
Currency | EUR | |
Annual sales | 71,755,303 (revenues, consolidated (2019) 2019-12-31) | |
Profit | -103,014,058 (2019-12-31) | |
Cash | 44,314,050 (2019-12-31) | |
* Document for �About Section�: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg. | ||
Record changed: 2020-04-26 |
Advertisement

More documents for MorphoSys (Group)
- [1] MorphoSys AG. (1/6/21). "Press Release: MorphoSys Appoints Sung Lee as Chief Financial Officer". Planegg....
- [2] MorphoSys AG. (12/1/20). "Press Release: Thomas Biegi Joins MorphoSys as Head of Corporate Communications". Planegg....
- [3] MorphoSys AG. (11/11/20). "Press Release: MorphoSys and Cherry Biolabs Announce Licensing of Hemibody Technology". Planegg & Würzburg....
- [4] MorphoSys AG. (11/11/20). "Press Release: Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab". Monrovia, CA, Planegg & Wilmington, DE....
- [5] MorphoSys AG. (10/13/20). "Press Release: Ad hoc – MorphoSys AG Launches an Offering of approx. EUR 325 Million Convertible Bonds". Planegg....
- [6] MorphoSys AG. (10/13/20). "Press Release: MorphoSys AG Successfully Places EUR 325 Million Convertible Bonds [Not for US, AU, ZA, JP, et al.]". Planegg....
- [7] MorphoSys AG. (9/30/20). "Press Release: MorphoSys Announces Departure of Jens Holstein, CFO, by Year End 2020". Planegg....
- [8] MorphoSys AG. (8/1/20). "Press Release: FDA Approves Monjuvi (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Planegg & Wilmington, DE....
- [9] MorphoSys AG. (7/14/20). "Press Release: MorphoSys' Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis". Planegg....
- [10] MorphoSys AG. (4/21/20). "Press Release: MorphoSys Appoints Roland Wandeler, Ph.D., as Chief Commercial Officer". Planegg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top